About: Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Sector: Healthcare
Industry: Biotechnology
Latest price: $0.37 (+0.16%)
KTTA NASDAQ Pasithea Therapeutics Corp
Pasithea Therapeutics Corp share price
KTTA price activity
Last Price
$0.370
Change (24hr)
0.00 USD (0.16%)
Volume
99.80K
Volume (4w avg)
-
Open
$0.37
Day Range
$0.36 - $0.39
Previous Close
$0.37
Last Trade
30 Oct, 8:00 pm GMT+0
Delayed
30 Oct, 8:00 pm GMT+0
KTTA price performance
Delayed
30 Oct, 8:00 pm GMT+0
KTTA Market Signals